Business
Preliminary Results for the Year Ended 31 Dec 2015
Preliminary Results for the Year Ended 31 Dec 2015.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 5824W Oxford Biomedica PLC 28 April 2016 \n\n \nOXFORD BIOMEDICA: PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2015\n \nOxford, UK - 28 April 2016: Oxford BioMedica plc (LSE: OXB), (\"OXB\" or \"the Group\"), a leading gene and cell therapy group, today announces its preliminary financial results for the twelve months ended 31 December 2015.\n \n \nOPERATIONAL HIGHLIGHTS (including post-period end): \n \n• Strong progress from LentiVector® delivery platform\n• Portfolio review in Q1 2016: focus on OXB-102, OXB-202 and OXB-302\n• OXB-102: On track for Phase I/II study in Parkinson's disease\n• OXB-202: Phase I/II study preparations continued; CTA filing planned for 2016 in corneal graft rejection\n• OXB-302: pre-clinical data demonstrates efficacy in tumour challenge model (CAR-T 5T4)\n• OXB-201 safety, tolerability, dose responsive protein expression in eye\n \n• Lentiviral vector production volumes increased by 71%\n \n• Investment in people, facilities and plant\n• Headcount increased from 134 to 231\n• New Yarnton facility operational\n• Harrow House extension and Windrush Court laboratories currently being validated\n \n• Partnerships broadened\n• Novartis extend beyond CTL019 with second CAR-T product\n• Immune Design LV305 collaboration extended and new IP licence\n• GSK acquired IP licence for two rare disease product candidates\n \n• Board strengthened\n• Dr Lorenzo Tallarigo joined as Chairman and Stuart Henderson joins as non-executive Director and Chair of Audit Committee in February 2016 and June 2016, respectively.\n \nFINANCIAL HIGHLIGHTS(1):\n \n• 28% growth in gross income (2) from £14.7 million to £18.8 million\n• 72% growth in income from process development and bioprocessing from £7.2 million to £12.4 million\n• Loss and total comprehensive expense f...